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Adverse reactions to commonly prescribed medications and to substances of abuse may result in severe toxicity associated with
increased morbidity and mortality. According to the Center for Disease Control, in 2013, at least 2113 human fatalities attributed
to poisonings occurred in the United States of America. In this article, we review the data regarding the impact of systemic
sodiumbicarbonate administration in themanagement of certain poisonings including sodium channel blocker toxicities, salicylate
overdose, and ingestion of some toxic alcohols and in various pharmacological toxicities. Based on the available literature and
empiric experience, the administration of sodium bicarbonate appears to be beneficial in the management of a patient with
the above-mentioned toxidromes. However, most of the available evidence originates from case reports, case series, and expert
consensus recommendations. The potential mechanisms of sodium bicarbonate include high sodium load and the development
of metabolic alkalosis with resultant decreased tissue penetration of the toxic substance with subsequent increased urinary
excretion.While receiving sodium bicarbonate, patients must bemonitored for the development of associated side effects including
electrolyte abnormalities, the progression of metabolic alkalosis, volume overload, worsening respiratory status, and/or worsening
metabolic acidosis. Patients with oliguric/anuric renal failure and advanced decompensated heart failure should not receive sodium
bicarbonate.
1. Introduction
In the USA, at least 34% of the population regularly takes at
least one prescription medication [1]. In the vast majority of
cases the use of such prescribedmedications provides clinical
benefit to patients. However, in some cases, thesemedications
may result in harm including a severe illness and death due
to intentional or unintentional overdose or as a result of
idiosyncratic drug reaction.
The goal of this article is to review the data and evidence
on the use of sodium bicarbonate in the management of
some pharmacological overdoses. We will first briefly review
the mechanisms of metabolic acidosis related biochemical
derangements since some of the overdoses are associatedwith
metabolic acidosis. Second, we will discuss the mechanism
of action, potential side effects, and typical dosing of sodium
bicarbonate.Third, we will review the literature on the role of
sodium bicarbonate in the management of sodium channel
blocker toxicities. Fourth, the data on the role of sodium
bicarbonate in the management of salicylate poisoning will
be provided. Finally, we will discuss the place of sodium
bicarbonate in the management of toxic alcohol ingestions.
The management of the toxicities mentioned above is
complicated, requiring additional measures than sodium
bicarbonate alone. Additional information on other aspects
of management can be obtained elsewhere and is not the goal
of this article.
2. Mechanism of Action and
Potential Complications of Sodium
Bicarbonate Therapy
Bicarbonate is an essential chemical regulating the acid-base
balance acting as a buffer [2]. Carbon dioxide (CO
2
) is a
Hindawi
International Journal of Nephrology
Volume 2017, Article ID 7831358, 8 pages
https://doi.org/10.1155/2017/7831358
2 International Journal of Nephrology
Table 1: Constituents and characteristics of commonly used crystalloids and plasma.
Solution Ph Na
+
(mmol/l)
Cl−
(mmol/l)
K+
(mmol/l)
Osmolality
(mOsmol/kg)
Plasma 7.35–7.45 136–145 95–105 3.5–5.0 275–295
Lactated Ringer 6.6 130 109 4 273
3% sodium chloride 5.0 513 513 0 1027
Normal saline (0.9%) 5.7 154 154 0 308
Half-normal saline (0.45%) 5.6 77 77 0 154
Dextrose 5% in water (D5W) 4.5 0 0 0 253
Bicarbonate (8.4%)∗ 8 1000 0 0 2000
∗
1 ampule contains 50 milliliters with 50mEq of sodium bicarbonate.
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Figure 1: An overview of the endogenous bicarbonate metabolism.
major byproduct of energy metabolism in living organisms
and a conjugate acid. Carbonic anhydrase enzyme facilitates
the chemical interaction between CO
2
and water producing
carbonic acid (H
2
CO
3
). Carbonic acid in turn dissociates
into bicarbonate (HCO
3
−) and hydrogen ion (H+) with the
latter being removed via kidneys. HCO
3
− can also bind extra
H+ producing carbonic acid. Indeed, all the reactions are
reversible and can go in any direction.
Sodiumbicarbonate (NaHCO
3
) is one of the few pharma-
cological agents aiming to mimic the endogenous effects of
HCO
3
−. Sodium bicarbonate is widely used in many clinical
situations including cardiac arrest [3, 4] and prevention of
contrast-induced renal failure [5] and in patients with differ-
ent types of metabolic acidosis (such as lactic acidosis and
diabetic ketoacidosis) [6], despite limited and controversial
evidence of its benefits. A simplified view on the bicarbonate
chemistry is provided in Figure 1. An overview of chemical
characteristics of commonly used crystalloids is presented in
Table 1.
The potential benefits of exogenous intravenous sodium
bicarbonate include the correction of metabolic acidosis with
its associated detrimental effects. However, the role of sodium
bicarbonate in the management of acute acidosis remains
controversial and may even be associated with potential side
effects and complications such as volume overload, metabolic
alkalosis, hypercapnia, hypokalemia, hypernatremia and
hyperosmolality, and ionized hypocalcemia [6, 7].
When administered, sodium bicarbonate dissociates into
a molecule of sodium and bicarbonate. The molecule of
bicarbonate in turn binds hydrogen converting into carbonic
acid with its subsequent dissociation into carbon dioxide and
water.
Carbon dioxide under normal conditions (intact lung
perfusion and ventilation) is exhaled, maintaining delicate
acid-base equilibrium. Under extreme conditions such as
shock states and impaired ventilation, carbon dioxide may
accumulate, leading to worsening acidosis [8, 9]. CO
2
pene-
trates cellular membranes easily, and through this ability may
exacerbate intracellular acidosis. Furthermore, by correcting
the systemic acidosis, sodium bicarbonate administration
may reduce respiratory drive leading to accumulation of
CO
2
in the central nervous system and associated adverse
neurological sequelae [10]. Serum potassiummay decrease as
a result of potassium shift into the cells in the patient with
metabolic acidosis treated with sodium bicarbonate. Other
potential adverse effects of administered sodium bicarbonate
may be related to its chemical features such as supraphys-
iologic sodium content and osmolality and alkaline pH
(comparative chemical features of sodium bicarbonate and
commonly used crystalloid solutions to plasma is presented
in Table 1). Ionized calcium may be decreased, such as in
metabolic alkalosis [11], which may cause tetany, decrease
cardiac contractility, and potentially predispose to cardiac
arrhythmias via prolongation of QT interval [12]. Serum
sodium and osmolality tend to increase which may lead
to cellular dehydration and systemic hypervolemia [13].
Lactic acid production may be increased in certain situations
via alkalosis dependent activation of 6-phosphofructokinase
enzyme [11, 14], and ketone bodies production may be
enhanced [15]. Decreased cardiac oxygen supply and arterial
vasoconstriction may also occur secondary to metabolic
alkalosis [16, 17]. Lastly, serious skin injuries can occur in the
setting of extravasation of hypertonic bicarbonate solutions,
and whenever possible it should be administered through
large bore intravenous lines or central venous lines.
Nevertheless, these adverse effects of sodium bicarbonate
such as an increase in systemic pH and high sodium load
may be useful in the management of certain pharmacological
toxicities and overdoses. Below we will review the utility and
likelymechanisms of sodiumbicarbonate in themanagement
of certain pharmacological toxicities: sodium channel block-
ers, salicylates,methanol and ethylene glycol poisonings, and,
finally, miscellaneous pharmacological toxicities.
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Table 2: List of some drugs with sodium channel blocking properties.
Class Representative medications
Class Ia antiarrhythmics Quinidine, Procainamide
Class Ib antiarrhythmics Lidocaine, Phenytoin
Class Ic antiarrhythmics Propafenone, Flecainide
Class III antiarrhythmics Amiodarone, Sotalol
Tricyclic antidepressants Amitriptyline, Doxepin
Antiepileptic medications Carbamazepine, Lamotrigine, Zonisamide, Lacosamide
Selective serotonin reuptake inhibitors Citalopram, Venlafaxine, Fluoxetine
Antihistamines Diphenhydramine
Miscellaneous Cocaine, local anesthetics, Thioridazine, Propranolol, Amantadine, Chloroquine,Hydroxychloroquine, Cyclobenzaprine
3. The Role of Sodium Bicarbonate in
the Management of Sodium Channel
Blocker Toxicities
Sodium channels are essential ion channels responsible for
transcellular sodium influx, primarily in cardiac and neuro-
logical tissue [18]. Pharmacological agents targeting sodium
channels are used in cardiac electrophysiology and neurology
(particularly in the areas of pain management and epilepsy)
[19, 20], as well as depression [21]. However, in cases of
excessive administration (intentional or not), sodium chan-
nel blockademay lead to serious cardiac dysfunction. A list of
some of the commonly used medications possessing sodium
channel blocking activities is presented in Table 2.
Tricyclic antidepressants (TCAs) are among the oldest
antidepressant medications that may also be used in the
management of mood disorders, generalized anxiety dis-
order, panic disorder, and neuropathic pain [21]. Despite
being an effective class, it is notorious for its narrow
therapeutic index and major side effect profile in cases of
overdose. TCAs were responsible for approximately 58% of
all antidepressant medications related fatal toxicities in 2013
[22]. The pathogenesis of TCA toxicity in regard to sodium
channel blockade is fundamental to the understanding of
other sodium channel toxicities, as is the therapeutic role
of intravenous (IV) sodium bicarbonate. It is important to
remember that the pharmacopathogenesis of TCA toxicities
is more complex than just sodium channel blockade and also
includes inhibition of muscarinic, alpha-1 adrenergic, and
antihistamine receptors [23]. Inhibition of cardiac sodium
channels may manifest on the electrocardiogram (ECG)
as the prolongation of QRS interval, new onset right axis
deviation, deep Swave in leadAVL, tall Rwave, and increased
Rwave to Swave ration in leadAVR and Brugada-like pattern
[24–28]. Clinically the effects of sodium channel block-
ade may present as cardiac arrhythmias and hemodynamic
instability [29]. Metabolic acidosis that occurs in cases of
hemodynamic deterioration potentiates the sodium blocking
activity of TCA medications by increasing the binding to
sodium channels [29–31]. Furthermore, TCA toxicity can
cause seizures resulting in persistence of metabolic acidosis
and propagation of detrimental metabolic disturbances. TCA
toxicity may be delayed and patients may initially appear
clinically well until decompensation occurs.
The scientific data on the use of sodium bicarbonate
in the management of TCA toxicity is predominantly orig-
inated from animal studies, case reports, and case series
[32, 33]. Sodium bicarbonate is commonly administered
as 8.4% solution 1-2mEq/kg (see Table 1) in cases of TCA
associated ECG abnormalities (such as QRS prolongation
> 100msec), hemodynamic compromise, and malignant
ventricular arrhythmias [34–36]. The benefit of sodium
bicarbonate in the setting of TCA overdose is probably due to
both an increase in serumpHand the increase in extracellular
sodium. Alkalization favors the neutral form of the drug
and reducing the amount of active cyclic antidepressants.
The high sodium load increases the electrochemical gradient
across cardiac cell membranes, potentially attenuating the
TCA-induced blockade of sodium channels [29, 30].
Based on clinical experience and available literature, the
majority of patients tend to respond via improvement in
hemodynamic and ECG parameters. 12-lead ECG of sodium
channel blocker toxicity before and after administration of
sodium bicarbonate is presented in Figures 2(a) and 2(b).
It may be necessary to continue sodium bicarbonate
after bolus doses in the form of IV infusion by diluting
2-3 ampules in 1 liter of dextrose 5% solution that is
nearly isotonic to plasma to decrease the risk of potential
rebound deterioration, while, on IV sodium bicarbonate,
patients should be monitored for evidence of fluid over-
load, respiratory status with advanced airway management
when indicated, electrolyte abnormalities (hypernatremia,
hypokalemia, hypocalcemia), andmetabolic alkalosis (poten-
tial target pH of 7.5). It is important to keep in mind that
because of its anticholinergic properties, the absorption of the
TCA may be delayed (due to delayed gastrointestinal motil-
ity); these patients should be closely monitored, and, in cases
of reemerging symptoms, sodium bicarbonate and other
therapies must be timely administered. Patients treated with
sodium bicarbonate should be monitored in the intensive
care setting with continuous monitoring and reassessment.
Frequency of laboratory testing and electrocardiographic
4 International Journal of Nephrology
(a) (b)
Figure 2: (a) Sodium channel toxicity on 12-lead ECG (taken from https://lifeinthefastlane.com).On this 12-lead ECG you can see regular wide
QRS tachycardia with no clear P waves, right axis deviation, tall R wave in AVR, and poor R wave progression in precordial leads. (b) Sodium
channel toxicity on 12-lead ECG after administration of sodium bicarbonate (taken from https://lifeinthefastlane.com).On this 12-lead ECG after
administration of sodium bicarbonate you can see atrioventricular dissociation with normal QRS, normal axis, and resolution of tall R wave
in AVR.
monitoring should be individualized. Blood gas analysis
(arterial or venous) and chemistry tests should be monitored
at least every 4 hours ormore frequently if clinically indicated
in patients treatedwith sodiumbicarbonate. It is important to
keep calcium and potassiumwithin normal range and replete
them if low to decrease the risk of cardiac arrhythmias.
Othermedications such as antiarrhythmics [36–38], non-
TCA antidepressants [39, 40], antiepileptic medications [41–
43], cyclobenzaprine [43, 44], propranolol [45], cocaine [46],
and certain antihistamines [47] may produce similar ECG
and clinical manifestations with favorable response to simi-
larly administered IV sodiumbicarbonate. Amantadine over-
dose may result in a similar cardiac sodium channel toxicity
though IV sodium bicarbonate was not specifically used in
the reported cases because of concomitant hypokalemia [48].
Animal research supports the beneficial effects of sodium
bicarbonate in case of thioridazine toxicity [49].
In conclusion, the literature on the use of sodium
bicarbonate in the management of sodium channel blocker
toxicities is limited to animal research and case series;
randomized trials are precluded due to ethical reasons. IV
sodium bicarbonate should be considered in the cases of
suspected sodium channel blocker toxicity associated with
hemodynamic and ECG abnormalities, given the very high
risk of adverse outcome without aggressive treatment [50].
Nevertheless, it is important to keep in mind that IV sodium
bicarbonate represents only a single tool in the management
of these toxicities and additional mechanisms of toxicity
may account for protean clinical manifestations of these
poisonings.
4. The Role of Sodium Bicarbonate in
the Management of Salicylate Toxicity
Salicylates are a group of pharmacological agents that include
aspirin, bismuth salicylate, and local skin preparations such
as salicylic acid and methyl salicylate (topical preparations
that rarely cause toxicity if used in an excessive amount or in
patients with skin damage leading to increased absorption)
[51, 52]. Aspirin, which is a major representative of the class,
has myriad of indications including cardiovascular diseases,
rheumatic diseases, and analgesia [53].
Analgesics, including aspirin, were the most common
etiology of all drug poisonings in the USA, with salicylate
poisoning leading to a fatal outcome in 34 patients out of
2113 deaths reported in 2013 [54]. The major mechanism of
action of aspirin is mediated via inhibition of cyclooxygenase
enzyme, resulting in decreased production of thromboxane
A2 and various prostaglandins [53]. However, with higher
dosages, other biochemical alterations may occur such as
uncoupling of oxidative phosphorylation in the electron
transport chain, resulting in heat release and stimulation of
respiratory center in the medulla [23]. The decrease in the
blood pH will favor formation of lipid soluble salicylic acid
which easily penetrates blood-brain barrier and undergoes
renal reabsorption [55].
Patients with salicylate toxicity typically present with
tinnitus, gastrointestinal complications (nausea, vomiting,
bleeding, and liver toxicity), hyperthermia (via uncoupling
of oxidative phosphorylation), pulmonary edema, andmixed
acid-base disorder (high anion gap metabolic acidosis and
respiratory alkalosis via stimulation of respiratory center in
the brain stem) [55].
Alkalinization with sodium bicarbonate is an essential
component of management of the aspirin-poisoned patient.
The first report in the English language medical literature of
the positive effect of sodium bicarbonate in the management
of salicylate-poisoned patient originates in 1948 [55].
Salicylic acid (HS) is a weak acid that exists in a charged
(deprotonated, sal−) and uncharged (protonated, H+) form:
H+ + sal− ⇔HS. Uncharged molecules (HS), unlike charged
molecules (sal−), can move easily across cellular barriers,
including the blood-brain barrier and the epithelium of the
renal tubule. Metabolic acidosis drives the above reaction
to the right and increases the plasma concentration of HS,
thereby promoting diffusion across the blood-brain barrier
into the CNS. In patients with salicylate intoxication, the
beneficial effects of sodium bicarbonate are mediated by the
production of metabolic alkalosis that decreases the amount
of lipid soluble salicylate and driving the above reaction
to the left resulting in decreased penetration into central
International Journal of Nephrology 5
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Figure 3: An overview of in vivo methanol and ethylene glycol metabolism.
nervous system and in increased urinary clearance [56].
As was discussed above, IV sodium bicarbonate may have
serious undesired effects including hypokalemia. The devel-
opment of hypokalemia is particularly detrimental to the
patients with salicylate-mediated toxicity because of increase
in hydrogen ion urinary excretion resulting in more acidic
urine and greater salicylate reabsorption and thus, should be
aggressively corrected [55, 56]. It is important to note that
mild alkalemia from a respiratory alkalosis (arterial pH <
7.55) is not a contraindication to sodium bicarbonate therapy
in salicylate poisoning. There is no scientifically validated
dosing of IV sodium bicarbonate (as in the management of
sodium channel blocker toxicities) but it is typically dosed as
1-2mEq/kg initially administered in bolus doses (see Table 1)
and then may be administered as a continuous IV infusion
after dilution in dextrose 5% solution [56]. The infusion
rate should be titrated to target a urine pH 7.5–8. Blood
gas analysis every two hours is indicated for monitoring to
prevent severe alkalemia (arterial pH > 7.60) [55, 56]. Patients
with anuric renal failure should not receive IV sodium
bicarbonate but rather be evaluated for renal replacement
therapy [55].
5. The Role of Sodium Bicarbonate in
the Management of Methanol and Ethylene
Glycol Poisoning
Methanol and ethylene glycol are alcohols commonly used
in household solutions such as various cleaners, solvents,
machine fluids, and antifreeze solutions [57]. There were
52430 exposures to alcohols resulting in 174 fatalities in 2013
[55]. The majority of toxicities arise either as a result of
a suicidal attempt or after drinking the toxic alcohol as a
substitute for ethanol [57].
To understand the basic pathogenesis of methanol and
ethylene glycol toxicity, it is important to review briefly the
metabolism in vivo.When ingested, bothmethanol and ethy-
lene glycol undergo an initial biochemical reaction catalyzed
by alcohol dehydrogenase (the same enzyme metabolizing
ethanol) converting the parent alcohol into formaldehyde and
glycolaldehyde, respectively. The metabolism of methanol
and ethylene glycol disrupts cellular energy metabolism
leading to cellular damage [58, 59]. The final products of
methanol and ethylene glycol metabolism are formic acid
and oxalic acid, respectively [57]. These end products result
in classic features of toxicity such as retinal toxicity caused
by methanol and renal injury mediated by oxalic acid. A
brief sketch of the in vivo methanol and ethylene glycol
metabolism is presented in Figure 3.
Clinical presentations of methanol and ethylene glycol
overlap, including central nervous system (CNS) symptoms
such as headache, altered mental status, and seizures. Retinal
toxicity and blindness are more specific for methanol; acute
kidney injury and hypocalcemia aremore typical for ethylene
glycol intoxication. Laboratory testing and diagnosis are
based on the presence of high anion gap metabolic acidosis,
the presence of a serum osmolal gap (the difference between
measured and calculated osmolality > 10), andmeasuring the
levels of toxic alcohols (used for confirmation; typically, this
testing is not time sensitive, and the treatment should not
be withheld in any patient suspected of having toxic alcohol
ingestion).
As in the management of other discussed toxidromes, the
literature on the benefits of IV sodium bicarbonate originates
from case reports and consensus guidelines [58, 59]. Ben-
eficial effects of sodium bicarbonate in the management of
methanol and ethylene glycol poisoning are believed to be
secondary to the formation and enhanced urinary clearance
of less toxic metabolites (formate) [59]. Acidemia leads to
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protonation of methanol and ethylene glycol metabolites
to uncharged molecules (e.g., formic acid and oxalic acid),
making them more likely to penetrate end-organ tissues
(such as the retina) and more likely to be reabsorbed across
the renal epithelium from the urine [58]. The suggested
regimen for IV sodium bicarbonate is similar to the above-
discussed indications. However, according to the consensus
guidelines, the therapy with IV sodium bicarbonate should
be strongly considered when pH falls below 7.3 with the
therapeutic aim of pH normalization. As is the case with any
treatment involving IV sodium bicarbonate, administration
necessitates frequent monitoring of metabolic parameters
(serum electrolytes and renal function), cardiopulmonary,
and renal status of the patient. Administration of sodium
bicarbonate should be used with caution in a patient with
oliguric/anuric renal failure (which is classically seen in
severe ethylene glycol toxicity). It is important to note that
symptomatic hypocalcemia should be corrected (the routine
correction of asymptomatic hypocalcemia is discouraged
because of the possible increase in the formation of calcium
oxalate crystals in ethylene glycol toxicity).
6. The Role of Sodium
Bicarbonate in the Management of
Miscellaneous Drug Toxicities
IV administration of sodium bicarbonate may result in
enhanced urinary excretion of certain chemicals through uri-
nary alkalinization [56].The urinary clearance of methotrex-
ate, phenobarbital, chlorpropamide, and fluoride is increased
after reaching urinary pH levels of 7.5–8.0 via formation of
lipid insoluble metabolite of the parent drug.
Metformin toxicity is another instance where sodium
bicarbonate may be used [60]. In rare circumstances (such
as acute illness and worsening renal function), metformin
administration may result in the development of lactic
acidosis that is believed to be secondary to mitochondrial
dysfunction, with a shift towards anaerobic glycolysis [60–
62].Though the literature on the role of systemic bicarbonate
administration in cases of metformin poisoning is very scant,
the use of IV sodium bicarbonate should be probably limited
to nonanuric patients with metformin-associated advanced
metabolic acidosis and pH < 7.1, given the questionable
efficacy and potential for adverse effects.
In conclusion, the data on the role of sodium bicarbonate
in the management of the above-listed medications is even
more limited and cannot be recommended as a first line.
7. Conclusion
Based on the available literature and empiric experience,
the IV administration of sodium bicarbonate appears to be
beneficial in the management of certain pharmacological
toxicities such as sodium channel blockers poisonings, sali-
cylate intoxication, and ingestion of methanol and ethylene
glycol. However, most of the data originates from case
reports, case series, and expert consensus recommendations.
The data on the management of metformin-associated lactic
acidosis, chlorpropamide, methotrexate, and phenobarbital
is even more limited. However, it seems very unlikely that
randomized controlled trials assessing the impact of sodium
bicarbonate will be performed due to ethical concerns.
The potential mechanisms of sodium bicarbonate admin-
istration include high sodium load, development ofmetabolic
alkalosis with resultant decreased tissue penetration of the
toxic substance, and its increased urinary excretion, while,
on IV sodium bicarbonate, the patients must be monitored
for the development of associated side effects including
electrolyte abnormalities (hypokalemia, hypocalcemia, and
hypernatremia), progression of metabolic alkalosis volume
overload, worsening respiratory status (volume overload and
increased CO
2
production), and worsening metabolic acido-
sis (paradoxical increase in lactic acid production secondary
to the activation of glycolytic enzymes). Frequency of lab-
oratory testing should be individualized. Blood gas analysis
(arterial or venous) and chemistry tests should be monitored
at least every 4 hours ormore frequently if clinically indicated
in patients treatedwith sodiumbicarbonate. It is important to
keep calcium and potassiumwithin normal range to decrease
the risk of cardiac arrhythmias.
Patients with oliguric/anuric renal failure and advanced
decompensated heart failure should not receive IV sodium
bicarbonate. IV administration of sodium bicarbonate rep-
resents only one aspect of the complex management of
medication and chemical toxicities, and, for a thorough
discussion of the management of these toxicities, the reader
is referred to focused reviews.
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